Feasibility of canakinumab withdrawal in colchicine-resistant familial Mediterranean fever
Authors' conclusion
It was possible to discontinue canakinumab successfully in more than half of the patients in 18 months.
Study context
- Population
- Paediatric colchicine-resistant FMF patients treated with canakinumab
- Participants
- 58 patients
- Exposure
- Canakinumab tapering/discontinuation protocol vs earlier management
- Group An = 33reference
- Group Bn = 25
- Outcome
- Canakinumab discontinuation
Methodological detailspaediatric, treatment discontinuation protocol
- Paediatric
- Treatment discontinuation protocol
Main finding
As reported in the abstract
| Group | Value | Discontinued at | Relapse with reinitiation (median follow-up 0.8 years, IQR 0.6-1.1) | Still clinically inactive on colchicine only |
|---|---|---|---|---|
| Group B | 18 events | end of 18 months | 2 | 16 |
Group B
Value18 events
Discontinued atend of 18 months
Relapse with reinitiation (median follow-up 0.8 years, IQR 0.6-1.1)2
Still clinically inactive on colchicine only16
Observational data: associations, not effects.
Further findings
| Outcome | Group A | Group B |
|---|---|---|
| Duration of canakinumab treatment | median 2.5 (IQR 1.9–3.7) years | — not stated in the abstract |
| Relapse with canakinumab restarted after discontinuation | 2 events | 2 events |
— not stated in the abstract
- Relapse with canakinumab restarted after discontinuation — Group B: remaining patients with clinically inactive disease on colchicine only
- 16
- Relapse with canakinumab restarted after discontinuation: Group B median follow-up 0.8 years (IQR 0.6-1.1)
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Feasibility of canakinumab withdrawal in colchicine-resistant familial Mediterranean fever. Rheumatology (Oxford). Published 24 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →